Aslanis, Vassilios http://orcid.org/0000-0003-0997-0081
Slack, Robert J. http://orcid.org/0000-0002-4372-9438
MacKinnon, Alison C.
McClinton, Catherine
Tantawi, Susan
Gravelle, Lise
Nilsson, Ulf J.
Leffler, Hakon
Brooks, Ashley
Khindri, Sanjeev K.
Marshall, Richard P.
Pedersen, Anders
Schambye, Hans
Zetterberg, Fredrik
Funding for this research was provided by:
Galecto Biotech AB
Article History
Received: 9 September 2022
Accepted: 21 February 2023
First Online: 13 March 2023
Declarations
:
: CM, RJS, RPM, SKK, ST, VA: employees, personal fees–Galecto Biotech AB. ACM, AP, FZ, HS, LG: employees, personal fees, patents (CA2,794,066, US13/832,672, WO/2014/067986)–Galecto Biotech AB. UJN: shareholder, consultant–Galecto Biotech AB. HL: shareholder, consultant, grant recipient–Galecto Biotech AB. AB: company fees for conduct of the phase 1 clinical trial, patents–Galecto Biotech AB.
: The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation and Good Clinical Practice. An independent ethics committee reviewed and approved the study protocol and its amendments. All participants freely gave their written informed consent before starting the study.
: Not applicable.
: Not applicable.
: Not applicable.